GTBP

GT Biopharma Inc

4.42

Nov 06 • 3:59 PM ET -0.12 (-2.64%)

4.40

Aftermarket • 5:00 PM ET -0.02 (-0.45%)

Healthcare Biotechnology USA Nano NASD

Peers: ATNM CNTX GDTC INMB MBRX NKTX JANX CUE ARTV KURA

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	9.11M
Enterprise Value	4.06M
Income	-32.76M
Sales	0.00M
Book/sh	2.00
Cash/sh	2.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Mar 17, 1980

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.21
P/C	1.80
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.38
Current Ratio	2.38
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-90.07
EPS next Y	-8.00
EPS next Q	-2.50
EPS this Y	93.56%
EPS next Y	25.58%
EPS next 5Y	65.26%
EPS past 3/5Y	31.76% 49.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	75.09%
Sales Y/Y TTM	-
EPS Q/Q	98.92%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-50.00% -

Insider Own	16.00%
Insider Trans	0.00%
Inst Own	5.07%
Inst Trans	3.35%
ROA	-342.05%
ROE	-1446.48%
ROIC	-618.74%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-23.51%
SMA50	-31.99%
SMA200	-53.04%
Trades

Shs Outstand	1.79M
Shs Float	1.73M
Short Float	16.12%
Short Ratio	4.18
Short Interest	0.28M
52W High	28.75 -84.63%
52W Low	4.38 0.91%
Volatility	8.99% 10.43%
ATR (14)	0.59
RSI (14)	35.05
Beta	0.85
Rel Volume	0.76
Avg Volume	66.78K
Volume	50,500

Perf Week	-16.92%
Perf Month	-25.84%
Perf Quarter	-44.85%
Perf Half Y	-52.88%
Perf YTD	-77.48%
Perf Year	-68.06%
Perf 3Y	-97.90%
Perf 5Y	-99.91%
Perf 10Y	-100.00%
Recom	1.00
Target Price	75.00
Prev Close	4.54
Price	4.42
Change %	-2.64%

Consensus

Strong Buy

Avg. Price Target

$75.00

Implied Upside

+1,596.8%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 02, 2024	Initiated	RROTH MKM	Buy	$11	+148.9%
May 24, 2021	Initiated	HH.C. Wainwright	Buy	$25	+465.6%
Apr 13, 2021	Initiated	RB. Riley Securities	Buy	$21	+375.1%
Mar 17, 2021	Initiated	RROTH Capital	Buy	$25	+465.6%

Oct-26-26 08:00AM	GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting (GlobeNewswire) -7.14%
Sep-15-26 09:15AM	GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma (GlobeNewswire) -22.61%
Sep-11-26 08:00AM	GT Biopharma to Host Live Company Presentation on the Development of TriKE Platform for Cancer Treatment, September 11, 2026 (GlobeNewswire) +39.32%
Aug-14-26 08:00AM	GT Biopharma Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
09:00AM	Loading…
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire) +11.30%
Jun-01-26 08:00AM	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives (GlobeNewswire) -7.57%
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire) +7.36%
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) +18.03%
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire) -7.51%
May-15-26 08:00AM	GT Biopharma Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.25%
May-14-26 08:30AM	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors (GlobeNewswire) +40.36%
Mar-11-26 07:00AM	GT Biopharma to Participate in the 38th Annual Roth Conference (GlobeNewswire) +5.67%
Mar-02-26 07:00AM	GT Biopharma Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-17-26 07:30AM	GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference (GlobeNewswire)
08:30AM	Loading…
Feb-03-26 08:30AM	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 (GlobeNewswire)
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-15-26 08:30AM	GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers (GlobeNewswire) +10.61%
08:01AM	EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment (Benzinga)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Dec-08-25 04:28PM	Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment (TheStreet) +6.56%
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Nov-19-25 08:00AM	GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials (ACCESSWIRE)
Nov-14-25 09:00AM	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +26.14%
Oct-23-25 09:00AM	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies (GlobeNewswire) +8.99%
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
08:45AM	Loading…
08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +43.67%
09:00AM	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies (GlobeNewswire)
08:31AM	EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers (Benzinga)
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.44%
08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire)
Oct-06-25 09:00AM	GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit (GlobeNewswire) +10.59%
Sep-04-25 07:00AM	GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 04:05PM	GT Biopharma Reports Second Quarter 2025 Financial Results (GlobeNewswire) -13.69% -7.59%
Aug-11-25 07:00AM	GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 (GlobeNewswire)
Jun-13-25 09:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
May-19-25 09:00AM	GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals (GlobeNewswire)
May-15-25 09:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
May-14-25 07:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
Mar-04-25 07:00AM	GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit (GlobeNewswire) -6.44%
Feb-25-25 02:00PM	GT Biopharma Announces Exercise of Warrants (GlobeNewswire) +21.18%
07:00AM	GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement (GlobeNewswire)
Jan-27-25 07:00AM	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies (GlobeNewswire) -15.70%
Nov-14-24 04:00PM	GT Biopharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Sep-26-24 09:15AM	GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-24-24 09:15AM	GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 (GlobeNewswire)
Aug-14-24 09:54PM	GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 (InvestorPlace)
04:05PM	GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-27-24 09:15AM	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia (GlobeNewswire) -7.08%
May-21-24 09:15AM	GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -28.21%
May-20-24 08:40AM	Why Is GT Biopharma (GTBP) Stock Up 143% Today? (InvestorPlace) +150.00%
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-16-24 10:53AM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024 (InvestorPlace) +7.21%
May-15-24 05:00PM	GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-24 09:53PM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-01-24 11:00AM	GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -6.16%
Dec-06-23 09:30AM	Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote FOR All Proposed Items at the Upcoming Special Meeting of Stockholders (GlobeNewswire)
Dec-04-23 09:30AM	GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia (GlobeNewswire) +6.91%
Nov-06-23 09:30AM	GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 09:00AM	GT Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 09:00AM	GT Biopharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 01:25PM	GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 (GlobeNewswire) -6.43%
May-15-23 05:00PM	GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
May-04-23 09:05AM	GT Biopharma Names Charles J. Casamento to the Board of Directors (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research) -5.79%
Mar-30-23 05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +18.33%
Feb-24-23 09:00AM	GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +5.00%
Dec-30-22 08:00AM	GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market (GlobeNewswire) -8.69%
Dec-14-22 07:30AM	GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer (GlobeNewswire) -6.67%
Dec-12-22 07:30AM	GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 (GlobeNewswire)
Nov-10-22 03:15PM	GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-03-22 09:00AM	GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting (GlobeNewswire)
Oct-31-22 05:15PM	GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire)
Oct-25-22 02:44PM	GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST (Newsfile)
Oct-06-22 08:18AM	GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Oct-04-22 04:10PM	GT Biopharma Announces Adjournment of Special Shareholders Meeting (GlobeNewswire)
Sep-12-22 09:34AM	GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies (GlobeNewswire)
Sep-08-22 07:30AM	GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September (GlobeNewswire) +12.75%
Aug-30-22 06:00PM	GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 (GlobeNewswire)
Aug-11-22 09:35AM	GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) -9.41%
Jun-10-22 08:00AM	GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress (GlobeNewswire) -5.21%
May-19-22 07:45AM	Will GT Biopharma (NASDAQ:GTBP) Spend Its Cash Wisely? (Simply Wall St.) +5.56%
May-16-22 08:01AM	GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) +6.74%
May-12-22 08:00AM	GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference (GlobeNewswire) +5.26%
Apr-11-22 07:30AM	GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 04:15PM	GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (PR Newswire) +7.04%
Mar-21-22 07:30AM	GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting (PR Newswire)
Mar-09-22 04:24PM	GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 (PR Newswire) +9.63%
Mar-03-22 07:30AM	GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 (PR Newswire)
Feb-24-22 07:30AM	GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences (PR Newswire) +12.86%
Feb-18-22 07:30AM	GT Biopharma Appoints Manu Ohri as Chief Financial Officer (PR Newswire) -10.98%
Jan-20-22 07:30AM	GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference (PR Newswire)
Jan-06-22 04:30PM	GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.74%

Show Previous News

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

PresidentMr. Michael Martin Breen L.L.B.

CFO & SecretaryMr. Alan Louis Urban CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GTBP

GT Biopharma Inc

Upgrade your Finviz experience